Abstract
Acquired hemophilia A (AHA) is a bleeding disorder caused by auto-antibodies to coagulation factor (F) VIII (Factor VIII inhibitor). Eradication of factor VIII inhibitor is vital therapy of AHA. Here, an AHA case is presented that was successfully treated with unconventional combination of low-dose rituximab and cyclosporine. Additionally, the literature about treatment of AHA with rituximab and/or cyclosporine AHA is also reviewed.